• /globalassets/images/homepage/homepage-slider.png

    Trusted partner and worldwide supplier to the diagnostic testing industry for over 30 years

    Advancing the development of molecular and serology diagnostics with innovative technology, quality controls, reagents, and biological materials

    Learn More

Find your tools for precision diagnostics


Precision Medicine

Next-gen sequencing tools and reference materials to support emerging precision medicine diagnostics


Clinical Laboratories

Quality controls and validation materials to monitor the performance of diagnostic assays


Assay Developers

Biological materials and reagents to develop and manufacture test kits for precision diagnostics


Life Science Researchers

Antibodies and immunoassay reagents for research and commercial assay development

Precision medicine diagnostics

With novel QC technology and biosynthetic reference materials for precision medicine diagnostics, SeraCare provides confidence in test results for oncology, non-invasive prenatal testing, and infectious disease.

Learn More

Collaboration and Partnerships

Join our team of early-access users to sample and evaluate new products as they emerge from our development pipeline. Partner with us and provide industry feedback to help shape and optimize QC products for the future.

Enroll Today

Over 30 years of experience

SeraCare is a trusted partner to the diagnostic testing industry. For over 30 years, we have evolved with technology to support the advancement of life science research, IVD development, and clinical laboratory testing.

Learn More

What people are saying

The interlaboratory comparisons made possible by this partnership [NIST and SeraCare] will speed NIST's efforts to overcome measurement challenges and advance cancer-detection technology broadly for the biomedical community. Studies have shown that circulating tumor DNA can be detected in many cancers and it can be used to monitor therapeutic progress. - Kenneth Cole, a group leader in NIST's Biosystems and Biomaterials Division
Seraseq reference materials offer a comprehensive and customizable set of mutations which are ideally suited to the comprehensive nature of the TOMA OS-Seq reagent kit. More importantly, we share the vision of a strong quality and regulatory approach when bringing validated NGS-based tumor profiling assays to market. - Federico Goodsaid, Ph.D., Vice President of Assay Development and Regulatory Affairs
Understanding and characterizing any NGS assay for liquid biopsy samples will require well-defined reference reagents. Standards like Seraseq ctDNA reference material allow the community to first understand ctDNA properties, optimize assays and then ultimately use ctDNA in innovative assays to detect and monitor cancer burdens within samples. In turn, this type of work will lay the foundation for transforming future cancer treatments. - Dr. Timothy Harkins, CEO of Swift Biosciences
It's really nice to work with SeraCare these years. I want to say thank you so much for all the efforts since we began working together. SeraCare has done an excellent job in supporting our business and I know that you will continue to do so in the future. I am always impressed with SeraCare's professionalism, passion, innovation, and attention to detail. Thank you again for everything!



  • https://blog.seracare.com/hubfs/iStock-516727646.jpg?t=1484772052385

    Multiplexed Reference Materials as Controls for Cardiomyopathy Diagnostic Next-Generation Sequencing

    Hypertrophic Cardiomyopathy (HCM) is a disease where the heart muscle is enlarged and a significant cause of sudden cardiac death, and is frequently asymptomatic.  HCM is commonly caused by a mutation in one of nine heart muscle genes that comprise the sarcomere, and occurs at a prevalence of about 1 in 500 in the general population. HCM is the leading cause of cardiac death in young athletes in the United States.

    Clinical genetic testing for mutations in the HCM-related genes has been ongoing for over a decade;  the GeneTest.org database reveals 105 laboratories offering some version of genetic testing.  While knowledge of prevalent pathogenic variants are available, the majority of variants remain private (that is, unpublished and not widely available). The move to NGS-based gene panels for HCM testing has lead to new challenges for test development, validation and routine quality control due to the inherent scarcity of samples, the cost of including numerous single mutations from these individual samples, and the lack of these materials for laboratories without a long history of testing.

    Read Our Blog